InvaGen Pharmaceuticals is recalling several lots of bupropion HCl extended-release tablets (generic Wellbutrin SR) because the medication failed dissolution testing during stability checks. This means the tablets may not release the active ingredient properly over time, which can result in the medication being less effective or releasing too quickly. These prescription tablets were distributed nationwide in 100 mg and 150 mg strengths in 60-count and 100-count bottles.
If the medication does not dissolve at the required rate, the patient may receive an incorrect dose, potentially leading to a lack of therapeutic effect for the treated condition.
Pharmacy refund and healthcare consultation
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.